Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | NMT1 | P30419 | 10/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502941 | 0.83 | LMNA (1.00) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16497565 | 0.83 | LMNA (0.79) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL1848084 | 0.81 | LMNA (0.70) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16502994 | 0.81 | SMN1; SMN2 (0.70) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16502936 | 0.80 | SMN1; SMN2 (0.68) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16502942 | 0.80 | L3MBTL1 (1.00) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16503034 | 0.80 | SMN1; SMN2 (0.68) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16817058 | 0.79 | LMNA (0.71) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16502992 | 0.79 | LMNA (0.71) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16503024 | 0.79 | NMT1 (0.69) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | LMNA 4064/4885HTT 4675/4885SMN1; SMN2 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.